RESUMO
OBJECTIVES: Advanced therapy medicinal products (ATMPs) are highly innovative therapies. Their costs and uncertain value claims have raised concerns among health technology assessment (HTA) bodies and payers. Little is known about how underlying considerations in HTA of ATMPs shape assessment and reimbursement recommendations. We aim to identify and assess key considerations that played a role in HTA of ATMPs underlying reimbursement recommendations. METHODS: A review of HTA reports was conducted of all authorized ATMPs in Scotland, The Netherlands, and England. Considerations were extracted and categorized into EUnetHTA Core Model domains. Per jurisdiction, considerations were aggregated and key considerations identified (defined as occurring in >1/assessment per jurisdiction). A narrative analysis was conducted comparing key considerations between jurisdictions and different reimbursement recommendations. RESULTS: We identified 15 ATMPs and 18 HTA reports. In The Netherlands and England most key considerations were identified in clinical effectiveness (EFF) and cost- and economic effectiveness (ECO) domains. In Scotland, the social aspects domain yielded most key considerations, followed by ECO and EFF. More uncertainty in evidence and assessment outcomes was accepted when orphan or end-of-life criteria were applied. A higher percentage of considerations supporting recommendations were identified for products with positive recommendations compared with restricted and negative recommendations. CONCLUSIONS: This is the first empirical review of HTA's using the EUnetHTA Core Model to identify and structure key considerations retrospectively. It provides insights in supporting and opposing considerations for reimbursement of individual products and differences between jurisdictions. Besides the EFF and ECO domain, the social, ethical, and legal domains seem to bear considerable weight in assessment of ATMPs.
Assuntos
Análise Custo-Benefício/métodos , Análise Custo-Benefício/estatística & dados numéricos , Avaliação da Tecnologia Biomédica/métodos , Avaliação da Tecnologia Biomédica/estatística & dados numéricos , Terapias em Estudo/economia , Análise Ética , Europa (Continente) , Humanos , Reembolso de Seguro de Saúde/economia , Estudos Retrospectivos , Terapias em Estudo/ética , IncertezaRESUMO
OBJECTIVES: Clinical innovation and research on maternal-fetal interventions have become an essential for the development of perinatal medicine. In this paper, we present an ethical argument that the professional virtue of integrity should guide perinatal investigators. METHODS: We present an historical account of the professional virtue of integrity and the key distinction that this account requires between intellectual integrity and moral integrity. RESULTS: We identify implications of both intellectual and moral integrity for innovation, research, prospective oversight, the role of equipoise in randomized clinical trials, and organizational leadership to ensure that perinatal innovation and research are conducted with professional integrity. CONCLUSIONS: Perinatal investigators and those charged with prospective oversight should be guided by the professional virtue of integrity. Leaders in perinatal medicine should create and sustain an organizational culture of professional integrity in fetal centers, where perinatal innovation and research should be conducted.
Assuntos
Pesquisa Biomédica , Assistência Perinatal , Perinatologia , Projetos de Pesquisa/normas , Terapias em Estudo , Pesquisa Biomédica/ética , Pesquisa Biomédica/métodos , Ética Profissional , Humanos , Consentimento Livre e Esclarecido , Assistência Perinatal/ética , Assistência Perinatal/tendências , Perinatologia/métodos , Perinatologia/tendências , Mal-Entendido Terapêutico , Terapias em Estudo/ética , Terapias em Estudo/métodosRESUMO
INTRODUCTION: Rare diseases, despite their low individual prevalence, affect a large number of children. Their management has considerably improved recently due to new treatments, modifying the diseases evolution without being totally curative. Since this raises many ethical dilemmas, we present a study about respecting the principles of medical ethics in the management of rare diseases in pediatrics. MATERIAL AND METHODS: We carried out a qualitative study in a French pediatric neurology department. In our study, we included health caregivers and parents of children being monitored for rare diseases and benefiting from innovative therapies. We conducted semi-structured interviews and, after transcription, we performed computerized and manual analysis. RESULTS: A total of 26 participants were included. Six main themes were addressed: rare diseases, science and medical research, general disease management, specific innovative treatments, neonatal screening, and cost of these treatments. Discussions centered on the children. Particular importance was given to the notions of information and the physician/family relationship. A major place is given to the treatment objectives and the improvement of quality of life. We also noted a sense of satisfaction with the current overall management of these diseases. CONCLUSION: Our study suggests that our current practice, including the use of innovative therapies, respects the four main ethical principles, from the points of view of both caregivers and parents.
Assuntos
Ética Médica , Pediatria/ética , Doenças Raras/terapia , Terapias em Estudo/ética , Gerenciamento Clínico , Feminino , Humanos , Entrevistas como Assunto , Masculino , Qualidade de VidaRESUMO
Emerging infectious diseases such as Ebola Virus Disease (EVD), Nipah Virus Encephalitis and Lassa fever pose significant epidemic threats. Responses to emerging infectious disease outbreaks frequently occur in resource-constrained regions and under high pressure to quickly contain the outbreak prior to potential spread. As seen in the 2020 EVD outbreaks in the Democratic Republic of Congo and the current COVID-19 pandemic, there is a continued need to evaluate and address the ethical challenges that arise in the high stakes environment of an emerging infectious disease outbreak response. The research presented here provides analysis of the ethical challenges with regard to allocation of limited resources, particularly experimental therapeutics, using the 2013-2016 EVD outbreak in West Africa as a case study. In-depth semi-structured interviews were conducted with senior healthcare personnel (n = 16) from international humanitarian aid organizations intimately engaged in the 2013-2016 EVD outbreak response in West Africa. Interviews were recorded in private setting, transcribed, and iteratively coded using grounded theory methodology. A majority of respondents indicated a clear propensity to adopt an ethical framework of guiding principles for international responses to emerging infectious disease outbreaks. Respondents agreed that prioritization of frontline workers' access to experimental therapeutics was warranted based on a principle of reciprocity. There was widespread acceptance of adaptive trial designs and greater trial transparency in providing access to experimental therapeutics. Many respondents also emphasized the importance of community engagement in limited resource allocation scheme design and culturally appropriate informed consent procedures. The study results inform a potential ethical framework of guiding principles based on the interview participants' insights to be adopted by international response organizations and their healthcare workers in the face of allocating limited resources such as experimental therapeutics in future emerging infectious disease outbreaks to ease the moral burden of individual healthcare providers.
Assuntos
Doenças Transmissíveis Emergentes/terapia , Surtos de Doenças/ética , Alocação de Recursos para a Atenção à Saúde/ética , Doença pelo Vírus Ebola/terapia , Ensaios Clínicos Adaptados como Assunto/ética , Adulto , África Ocidental/epidemiologia , Feminino , Pessoal de Saúde/ética , Humanos , Entrevistas como Assunto , Masculino , Pessoa de Meia-Idade , Terapias em Estudo/éticaRESUMO
The pediatrician has a privileged relationship with a child with infantile spinal muscular atrophy (SMA). At all times, he/she must be the child's mentor, promoting a comprehensive approach and support in order to ensure the best possible solution for the patient's autonomy. In all circumstances, an ethical stance is essential. After a reminder on the notions of ethics of care, we will address various ethical questions encountered through three critical situations during the care of a child with infantile spinal muscular atrophy: the announcement of the diagnosis, the transmission of information on innovative therapies, and palliative care and end-of-life support. © 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
Assuntos
Cuidados Paliativos/ética , Relações Médico-Paciente/ética , Relações Profissional-Família/ética , Atrofias Musculares Espinais da Infância/terapia , Assistência Terminal/ética , Terapias em Estudo/ética , Revelação da Verdade/ética , Adolescente , Beneficência , Criança , Pré-Escolar , Humanos , Lactente , Consentimento Livre e Esclarecido/ética , Cuidados Paliativos/psicologia , Educação de Pacientes como Assunto/ética , Pediatria/ética , Autonomia Pessoal , Atrofias Musculares Espinais da Infância/diagnóstico , Atrofias Musculares Espinais da Infância/psicologia , Assistência Terminal/psicologia , Terapias em Estudo/psicologiaRESUMO
In recent years, remarkable progress has been made in the fundamental research and on clinical development of cell therapy. Although China has launched a series of regulations to establish a proper regulatory framework that facilitates the development of cell therapy products, the regulatory framework has not been able to meet the country's regulatory requirements. This article introduced the development of regulation and current regulatory pathways for cell therapy in China and identified the main challenges in clinical studies. China has recently tightened its policy on cell therapy clinical studies after medical chaos occurred in the area of cell therapy over the past few years. Currently the regulatory jurisdiction between NMPA and NHC are not very clear, especially for clinical somatic cell research, further efforts are necessary to establish a legislative system with a clear and functional regulatory framework for cell therapy.
Assuntos
Terapia Baseada em Transplante de Células e Tecidos/normas , Regulamentação Governamental , Acessibilidade aos Serviços de Saúde/legislação & jurisprudência , Acessibilidade aos Serviços de Saúde/normas , Terapias em Estudo/normas , Terapia Baseada em Transplante de Células e Tecidos/ética , China/epidemiologia , Ensaios Clínicos como Assunto/ética , Ensaios Clínicos como Assunto/legislação & jurisprudência , Ensaios Clínicos como Assunto/normas , Acessibilidade aos Serviços de Saúde/ética , Humanos , Terapias em Estudo/éticaRESUMO
TITLE: L'éthique des essais thérapeutiques. ABSTRACT: La pandémie de COVID-19 a conduit certains acteurs reconnus de la médecine à renoncer aux méthodes codifiées de la recherche médicale au profit d'affirmations établies dans l'urgence et sans réelle évaluation scientifique. Autant l'on peut comprendre que certains praticiens recourent à ce qui leur est ainsi proposé, autant cette confusion entre action dans l'urgence et recherche scientifique serait lourde de conséquences si elle venait à se généraliser, et cela à de multiples points de vue : image et rôle de la science, qualité et éthique de la recherche médicale et en fin de compte sort des malades soumis à des traitements mal évalués. Ce sont ces questions qui motivent la mise au point qui suit sur les questions d'éthique associées de longue date aux « essais thérapeutiques ¼, cette procédure rationnelle d'acquisition dans les meilleurs délais d'informations fiables sur les avantages et les risques des traitements dont on envisage l'éventuelle utilisation.
Assuntos
Ensaios Clínicos como Assunto/ética , Ética Médica , COVID-19 , Ensaios Clínicos como Assunto/legislação & jurisprudência , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/terapia , Serviços Médicos de Emergência/ética , Serviços Médicos de Emergência/história , Serviços Médicos de Emergência/legislação & jurisprudência , Serviços Médicos de Emergência/métodos , História do Século XXI , Humanos , Consentimento Livre e Esclarecido/ética , Consentimento Livre e Esclarecido/legislação & jurisprudência , Consentimento Livre e Esclarecido/normas , Conhecimento , Legislação Médica , Pandemias , Pneumonia Viral/epidemiologia , Pneumonia Viral/terapia , Melhoria de Qualidade , Qualidade da Assistência à Saúde/ética , Qualidade da Assistência à Saúde/legislação & jurisprudência , Projetos de Pesquisa/legislação & jurisprudência , Projetos de Pesquisa/normas , Terapias em Estudo/ética , Terapias em Estudo/normasRESUMO
Background: With growing transplant wait times, clinical trials are evaluating the safety and efficacy of transplanting HCV-infected donor (HCV+) organs into HCV-noninfected recipients (HCV D+/R-). Such transplants raise ethical questions about safety, consent, and access to organs. Methods: We interviewed eight of the ten total HCV D+/R- transplant recipients enrolled in a pilot clinical trial examining the safety and feasibility of these novel transplants regarding their experiences in the trial, including their decision-making and perceptions of the informed consent process. Results: All interviewees reported positive experiences and expressed confidence regarding their decision to participate. Participants accepted an HCV + organ based on their assessments of the risks and potential benefits of HCV D+/R- transplants. For many, the risks of HCV were minimal compared to the risks of not receiving a transplant. All participants recalled providing informed consent, reporting that the process was thorough and that all their questions were addressed. Participants did not regret receiving an HCV D+/R- transplant and did not report experiencing stigma. However, given their understanding of HCV cure rates in the general population and the survival benefit associated with kidney transplantation, participants may have conflated research regarding HCV D+/R- transplantation with clinical care, suggesting a potential therapeutic misconception. Conclusions: Recipients of experimental HCV D+/R- transplants generally seemed to recognize the risks and benefits of these novel transplants and did not regret participating. Such salutary reported experiences are important in assessing the appropriateness of further research into the feasibility of HCV D+/R- transplants.
Assuntos
Hepatite C/etiologia , Transplante de Rim/ética , Terapias em Estudo/ética , Transplantados/psicologia , Idoso , Tomada de Decisões/ética , Feminino , Hepacivirus , Humanos , Consentimento Livre e Esclarecido/ética , Masculino , Projetos Piloto , Pesquisa Qualitativa , Medição de Risco , Mal-Entendido Terapêutico , Estados Unidos/epidemiologiaRESUMO
This article provides an ethical analysis of the U.S. practice guideline update on disorders of consciousness. Our analysis focuses on the guideline's recommendations regarding the use of investigational neuroimaging methods to assess brain-injured patients. Complex and multifaceted ethical issues have emerged because these methods alter the clinical understanding of consciousness. We address issues of false hope, patient suffering, and cost. We argue that, in spite of these concerns, there is significant benefit to using neuroimaging to assess brain-injured patients in most cases.
Assuntos
Lesão Encefálica Crônica/diagnóstico por imagem , Transtornos da Consciência/diagnóstico por imagem , Neuroimagem/ética , Guias de Prática Clínica como Assunto , Terapias em Estudo/ética , Adulto , Estado de Consciência/ética , Análise Custo-Benefício/ética , Humanos , Masculino , Status Moral , Qualidade de Vida , Estados UnidosRESUMO
Patients with cancer who have exhausted standard treatments often seek access to investigational drugs. Often, however, such access is unavailable, due to either the unavailability of a trial, lack of an open recruiting spot on the trial, even when the trial itself is open, or the inability of the patient to meet one or more trial eligibility criteria. In such settings patients often seek access to investigational agents outside of a trial. The federal "Right to Try" legislation was passed to create an additional avenue, different from the FDA's Expanded Access, or "Compassionate Use" Program, through which patients might obtain access to investigational drugs. A year after this legislation was signed into law, there remains both a limited awareness of it and a substantial degree of misunderstanding on the part of those who are aware of it. The law creates an avenue to greatly facilitate off-study administration when patient, physician, and the manufacturer are all in agreement regarding the off study use of an eligible investigational agent. The law does not, however, empower a patient to impose a demand on either a provider or a drug manufacturer, nor does it require any entity to provide financial coverage for the drug. Eligible drugs are those which are not approved by the FDA for any indication, have completed a phase I trial, have an ongoing pivotal trial, and have an active registration plan. We review the specific law with commentary on its implications for improved access to investigational drugs outside of clinical trials.
Assuntos
Aprovação de Drogas/legislação & jurisprudência , Drogas em Investigação/uso terapêutico , Neoplasias/tratamento farmacológico , Direitos do Paciente/legislação & jurisprudência , Terapias em Estudo/ética , Humanos , Estados Unidos , United States Food and Drug AdministrationRESUMO
Consent to any experimental procedure, even when offered as therapeutic, involves extensive discussion between patient-subjects and clinician-researchers. Decision making should be shared with a focus on potential risks and benefits of enrolling in a protocol. Just as patients who underwent nonexperimental interventions might experience regret or reconsider autonomously made choices, patient-subjects who are undergoing or who have undergone experimental therapies should be afforded latitude to reconsider their decisions. Although clinician-researchers tend to be deeply invested in gathering data about patient-subjects' experiences, they are obligated to express respect for patient-subjects' fundamental right to stop being enrolled in research.
Assuntos
Tomada de Decisões/ética , Transplante de Mão/ética , Transplante de Mão/psicologia , Consentimento Livre e Esclarecido/ética , Consentimento Livre e Esclarecido/psicologia , Humanos , Masculino , Avaliação de Resultados em Cuidados de Saúde/ética , Autonomia Pessoal , Relações Profissional-Paciente/ética , Relações Pesquisador-Sujeito/ética , Respeito , Medição de Risco , Terapias em Estudo/ética , Terapias em Estudo/psicologia , Resultado do Tratamento , IncertezaRESUMO
A goal of hand and upper extremity transplantation is to return motor and sensory function to an amputee. Given the integral roles of one's hands in activities of daily living and social interaction, however, restoring psychosocial well-being should also be a priority. Based on the authors' experience, double-hand transplantation success depends significantly on strong social support, physical rehabilitation, medication adherence, and social integration. Because caregiving is demanding, tasks should be distributed among members of a patient's family and social network. This article analyzes how to respond to an overwhelmed caregiver by drawing on solid organ transplant literature about caregiver fatigue.
Assuntos
Cuidadores/psicologia , Efeitos Psicossociais da Doença , Transplante de Mão/reabilitação , Qualidade de Vida , Papel (figurativo) , Tomada de Decisão Clínica/ética , Humanos , Sistemas de Apoio Psicossocial , Estresse Psicológico , Terapias em Estudo/éticaAssuntos
Cirurgia Geral/métodos , Procedimentos Cirúrgicos Operatórios/métodos , Terapias em Estudo/métodos , Cirurgia Geral/educação , Cirurgia Geral/ética , Humanos , Procedimentos Cirúrgicos Operatórios/educação , Procedimentos Cirúrgicos Operatórios/ética , Terapias em Estudo/ética , Estados UnidosRESUMO
BACKGROUND: Nowadays one of the most critical aspects of innovative cell-based therapies is the unregulated industry, as it is becoming a competitor of the regulated system. Many private clinics, worldwide, advertise and offer cell-based interventions treatments directly to the consumer and this poses a risk to both vulnerable patients and health systems. Several countries have implemented Compassionate Use Programmes (CUP) that provide patients with medicines that have not yet completed the approval pathway, in the event that no reasonable alternative exists. Recently, in the public discourse, compassionate use has been increasingly associated with a patient's right to try. Thus, the aim of this study was to assess public knowledge of the clinical trials process with specific reference to innovative stem cell treatments, and trust in the institutions responsible for regulatory activities. We also asked people about their "right" to use unregulated therapies. METHODS: We developed an ad hoc questionnaire on three main areas of concern and administered it to 300 people in the patient waiting room at an Italian university hospital. RESULTS: Our findings suggest that people have a good knowledge of the clinical trials process and trust in healthcare institutions. Nonetheless, one person in two believes it is a right to use unregulated therapies. CONCLUSIONS: We stress the need, in the age of cellular therapies, for a commitment to support vulnerable patients and to strengthen awareness among the public about the substantial boundary that differentiates experimental therapies from unproven therapies. There should not be a "right to try" something that is unsafe but rather approved treatments and in line with good clinical practice. The trend, which emerged on this issue from our study, is quite different, confirming the urgent need to improve health information so that it is as complete as possible.
Assuntos
Ensaios de Uso Compassivo , Direitos do Paciente , Direito à Saúde , Transplante de Células-Tronco , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Ensaios Clínicos como Assunto , Ensaios de Uso Compassivo/ética , Ensaios de Uso Compassivo/legislação & jurisprudência , Cultura , União Europeia , Feminino , Humanos , Itália , Masculino , Turismo Médico , Pessoa de Meia-Idade , Direitos do Paciente/ética , Direitos do Paciente/legislação & jurisprudência , Segurança do Paciente , Direito à Saúde/ética , Direito à Saúde/legislação & jurisprudência , Risco , Transplante de Células-Tronco/ética , Transplante de Células-Tronco/legislação & jurisprudência , Terapias em Estudo/ética , Confiança , Estados Unidos , Adulto JovemRESUMO
Provisions for post-trial access (PTA) of the experimental intervention are required before the start of a clinical trial. Although there has been ample attention for PTA in the context of preventive vaccine research, discussions on PTA barely include maternal vaccine trials in which mother-infant pairs are exposed to the intervention. In maternal vaccination trials, specific PTA arrangements are required because pregnancy is transient and PTA may apply to the next pregnancy or the child. In this article, we examine the application and adherence to PTA in the context of maternal vaccine trials. We focused on differences between publications before and after 2000 when international ethical guidance documents formalized PTA requirements. Randomized maternal vaccine trials were included after a systematic search for clinical trials in phases II and III with a maternal vaccine as intervention. We used PTA as defined at the time of publication in the World Medical Association's Declaration of Helsinki (DoH) or in the ethical guidelines of the Council for International Organizations of Medical Sciences (CIOMS). In addition, we investigated whether PTA was included in the trial design. Therefore, we contacted principal investigators (PI's) of the publications found in the review to fill out a questionnaire regarding provisions for PTA. Before and after 2000, no trial articles examined in the systematic review described PTA in their trial publication (0/7, 0% and 0/17, 0%, respectively). In addition, more than half of the PI's of the trials found were not familiar with PTA recommendations in international ethical guidelines. Most cases of PTA included making knowledge available by publishing the results of the trial. The revision of the DoH in 2002 and the CIOMS ethical guidelines in 2002 has not resulted in increased PTA provisions for maternal vaccination trials. PTA is a shared responsibility of various stakeholders including sponsors, Institutional Review Boards, regulators, political entities, and researchers. Inclusion of PTA provisions in trial protocols and publications on maternal vaccination trials is essential to increase transparency on the form and content of these provisions.
Assuntos
Ética em Pesquisa , Guias como Assunto , Direitos do Paciente , Ensaios Clínicos Controlados Aleatórios como Assunto/ética , Experimentação Humana Terapêutica/ética , Vacinação , Códigos de Ética , Feminino , Humanos , Gravidez , Ensaios Clínicos Controlados Aleatórios como Assunto/normas , Responsabilidade Social , Terapias em Estudo/ética , Vacinação/éticaAssuntos
Transtornos Mentais/terapia , Relações Metafísicas Mente-Corpo , Psiquiatria , Religião e Psicologia , Criança , Ética Médica , Humanos , Transtornos Mentais/psicologia , Relações Metafísicas Mente-Corpo/ética , Relações Metafísicas Mente-Corpo/fisiologia , Neurociências/ética , Neurociências/métodos , Neurociências/tendências , Psiquiatria/ética , Psiquiatria/métodos , Psiquiatria/tendências , Psicopatologia/ética , Psicopatologia/métodos , Psicopatologia/tendências , Religião e Medicina , Terapias em Estudo/ética , Terapias em Estudo/métodos , Terapias em Estudo/tendênciasRESUMO
Innovative practice occurs when a clinician provides something new, untested, or nonstandard to a patient in the course of clinical care, rather than as part of a research study. Commentators have noted that patients engaged in innovative practice are at significant risk of suffering harm, exploitation, or autonomy violations. By creating a pathway for harmful or nonbeneficial interventions to spread within medical practice without being subjected to rigorous scientific evaluation, innovative practice poses similar risks to the wider community of patients and society as a whole. Given these concerns, how should we control and oversee innovative practice, and in particular, how should we coordinate innovative practice and clinical research? In this article, I argue that an ethical approach overseeing innovative practice must encourage the early transition to rigorous clinical research without delaying or deferring the development of beneficial innovations or violating the autonomy rights of clinicians and their patients.